# Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma

> **NCT00090987** · PHASE2 · COMPLETED · sponsor: **AIDS Malignancy Consortium** · enrollment: 30 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00090987
- **Lead sponsor:** AIDS Malignancy Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-06-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00090987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00090987, "Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00090987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*